A Pharmaco-Therapeutic Study of Ashwagandha [Withania Somnifera (Linn.) Dunel] And Amrita [Tinospora Cardifolia (Wild.) Miers] On Sandhivaat W.S.R To Osteo-Arthritis.

Print ISSN: 2581-7884 | Volume III | Issue 32 | July-September 2025 | Paper ID – E 32/ 04

Research Article। Eastern Scientist

Dharmendra Mondal¹, Raman Ranjan², Alok Ranjan³, Subhash Chandra⁴, Ganesh Prasad Gupta⁵.
 
₁Ayurvedic Medical Officer, Government of Bihar.
₂Assistant Professor, Dravyaguna Department, Government Ayurvedic College, Patna.
₃ Assistant Professor, Dravyaguna Department, Government Ayurvedic College, Patna.
₄Director, L.N.J.P, Bone & Joint Superspeciality Hospital, Rajbanshi Nagar, Patna, Bihar
⁵ Associate Professor, Dravyaguna Department, Government Ayurvedic College, Patna.
 

---

 ABSTRACT-

Sandhivata is a dhatu kshyajanya vata vyadhi. It is an age-related disorder. Based on symptoms, it can be correlated with osteoarthritis. It is a multifactorial, non-inflammatory degenerative disorder. Vata is the main factor responsible for producing Sandhivata, and its description is widely narrated in almost all the classical texts. In the present study named as A pharmaco-therapeutic study of Ashwagandha [withania somnifera (Linn.) Dunel] and Amrita [Tinospora cardifolia(wild.) miers] on sandhivaat w.s.r to Osteo-Arthritis, an attempt has been made in the management of sandhivaat. This present study aim to find a method of treatment to symptomatic relief without any side effect. Ashwagandha and Amrita are Tikta Dravya having vatahar, aganidipaniya, and Rasayana properties that redeem the vitalized vata and degenerative changes in Sandhivata. The present study is taken upto evaluate the effect of Ashwagandha churna (Group-A), Amrita satva (Group-B) and combine effect of both Ashwagandha and Amrita satva (Group-C) and compaire the effect of all three groups. The Ashwagandha of Group-A is more efficient than that of Group-B. (Amrita). However, Group-C (Ashwagandha + Amrita) was shown to be more effective in treating the patients than either Group-A or Group-B. The trial drug has given promising results by showing improvement in the signs and symptoms of Sandhivata.

 सारांश- (संधिवात एक 'धातु क्षयजन्य वात व्याधि' है। यह उम्र से संबंधित एक विकार है। इसके लक्षणों के आधार पर इसकी तुलना ऑस्टियोआर्थराइटिस से की जा सकती है। यह एक बहु-कारकीय, गैर-सूजन-संबंधी, अपक्षयी विकार (multi-factorial, non-inflammatory degenerative disorder) है। वात संधिवात उत्पन्न करने का मुख्य कारक है, और इसका वर्णन लगभग सभी शास्त्रीय ग्रंथों में व्यापक रूप से किया गया है।

'A pharmaco-therapeutic study of Ashwagandha [withania somnifera(Linn.) Dunel] and Amrita [Tinospora cardifolia(wild.) miers] on sandhivaat w.s.r to Osteo-Arthritis' नामक इस अध्ययन में, संधिवात के प्रबंधन के लिए एक प्रयास किया गया है। इस अध्ययन का उद्देश्य बिना किसी दुष्प्रभाव के लक्षणों से राहत के लिए उपचार का एक तरीका खोजना है। अश्वगंधा और अमृता 'तिक्त द्रव्य' हैं, जिनमें वातहर, अग्निदीपनीय और रसायन गुण होते हैं, जो संधिवात में वात और अपक्षयी परिवर्तनों को ठीक करते हैं।

यह अध्ययन अश्वगंधा चूर्ण (समूह-ए), अमृता सत्व (समूह-बी) और अश्वगंधा और अमृता सत्व (समूह-सी) के संयुक्त प्रभाव का मूल्यांकन और तीनों समूहों के प्रभाव की तुलना करने के लिए किया गया है। समूह-ए (अश्वगंधा) का प्रभाव समूह-बी (अमृता) से अधिक प्रभावशाली है। हालांकि, समूह-सी (अश्वगंधा + अमृता) को समूह-ए या समूह-बी की तुलना में रोगियों के इलाज में अधिक प्रभावी दिखाया गया है। परीक्षण दवा ने संधिवात के लक्षणों और संकेतों में सुधार दिखाकर आशाजनक परिणाम दिए हैं।)

INTRODUCTION

Introduction- Health is the supreme foundation for the achievement of a happy life. Humans must comprehend the ideal concept of health and dhatu samya in order to accomplish their primary goal in life, which is to achieve ‘Hitayu’ and ‘Sukhayu’.Due to the modernization and resulting sedentary lifestyle, younger and older people are complaining of different "Vatika disorders". In Ayurveda, the decade wise ageing process is described. There are two categories of ageing, kalaja and akalaja. All khatu undergoes Kshaya in vridhavastha, which results in vata prakopa and makes the person susceptible to a wide range of diseases.

  Sandhivata stands at the top of the list, and it is described under Vata vyadhi in all the Samhita and Sangraha Grantha. Among the three doshas, Vata is responsible for all chestha. Acharya Charak was the first person who described the disease separately named "Sandhigata anila", but it is not included under the 80 types of nanatmaja vyadhi . Acharya Vagabhatta has also considered Vata vyadhi as a maharoga. Sandhivata is a Vata Vyadhi, occurring when the patient attains the Vatika phase of life, i.e. after 50 years of age. As in this period, Vata Dosha is predominant, mainly occurring due to Prakopa of Vata. This Vata Prakopa can occur for either of three reasons.

•          Dhatukshyajanya Vata Prakopa

•          Swanidana Sevanajanya Vata Prakopa

•          Avaranjanya Vata Prakopa.

  Osteoarthritis is one of the most common arthritic conditions increasing in the elderly population. It is a slow-progressing degenerative joint disease. Many studies reported that these degenerative changes in joints arise from the age of 30 years by the age of 70 years, 80% of the people may have radiographic evidence of Osteoarthritis although only 25% may have symptoms. The symptoms, such as pain and inflammation, appear in middle age. The association with ageing is strong: the prevalence of OA increases exponentially beyond the age of 50, and about 80% to 90% of individuals have evidence of the disease by age 65. Osteoarthritis is a major cause of morbidity and disability, limiting activity and impairing quality of life, especially among the elderly. The primary complaints of patients with osteoarthritis are pain and difficulty in movement of joints.

By considering all the described facts, it can be concluded that the complete cure of the disease still has the status of a miracle. So, we have here made an effort to find a safe and complete solution for the disease with the help of Ayurvedic medicine, which is described in the context of Sandhivata chikitsa.

 According to Bhawapraksh, Ashwagandha minimizes the Vata (anila) Dosha, shoth, and kshaya due to its ushna virya, Balya, and Rasayan property. Its Doshakarm is Kapha-Vata shamak. Ashwagandha has pharmacological action like Anti inflammatory activity, Immunomodulation and Hematopoiesis, Adaptogenic Action, Antiparkinsonian properties, Anti-Malignant Activity, Anti-Aging, Hypolipidemic effect. According to Acharya charak, Amrita have Vatahar property and its Doshakarm is Tridosh shamak.   Amrita has pharmacological action like Anti-osteoporotic effects, Immunomodulatory activity, Antidiabetic activity, Hypolipidemic effect, Antistress activity, Hepatic disorder, Wound healing, Anticancer property.    

Aims and Objective                                                  

 A pharmaco-therapeutic Study of Ashwagandha [Withania somnifera (Linn.) Dunal] and Amrita [Tinospora cordifolia (Willd.) Miers] on Sandhivata w.s.r. to Osteo-Arthritis.

Material and methods

A total of 60 clinically diagnosed and confirmed cases of sandhivaat were registered for the present clinical trial and randomly divided into three group for this study.  Out of which 53 patients completed the course of treatment. The cases were selected from the O.P.D of Government Ayurvedic College & Hospital and L.N.J.P. Bone & Joint Super Specialty Hospital, Rajbanshinagar, Patna after taking informed written consent.

Criteria for selection of patients

Inclusion Criteria: -

•Patients of Age group between 31 – 70 years and Patient willing for the trial.

•Patients have Selected signs and symptoms based on both Ayurvedic and Modern context like, Sandhishula (pain), Sandhishotha (swelling), Akunchana Prasarana Vedana (pain during flexion & extension), Sandhigraha (stiffness), Sphutana (Crepitus), Sparsha-Asahyata (Tenderness) etc.

 

Exclusion Criteria: -

•          Less than 31 year and more than 70 years.

•          Traumatic injury of bone.

•          During pregnancy.

•          Patient having severe diseases like heart diseases, HIV, Hepatitis B and other severe illness.

 

Study design: A Randomized open clinical study.

Study type: Interventional and diagnostic.

Intervention model: Three group assignment.

Allocation: Randomized ( By lottery process )

Masking: open level.

Primary purpose: Efficacy and safety of selected drug.

End point: Treatment.

Sample size (number of subjects); 20 in each group , ie 60 in the centre.

Level of study: O.P.D & I.P.D level.

•Ethical committee clearance: Before recruitment of subjects in present clinical trial, approval from the approved by Institutional ethics committee (Letter number- 1188 date- 30 September 2020) and has been registered in Clinical Trial Registry India (CTRI) Under CTRI NO- CTRI / 2021 /10 /037554.

Admistration of drug: Clinically diagnosed and registered patients of Sandhivaat (osteoarthritis) were randomly divided into the following three group.

GROUP- A: Patients were treated with trial drug Ashwagandha churna – 6 gm / day in two divided doses.

GROUP – B: Patients were treated with trial drug Amrita Satva 1 gm/ day in two divided doses.

GROUP- C: Patients were treated with trial drug Ashwagandha  Churna 6 gm with Amrita Satva 1 gm/ day in two divided doses.

                                  Method of Study

 

1.Consent: - A written informed consent was taken on prescribed proforma before the inclusion of patient in trial. They were brief about merits and demerits of research plan before taking consent.

2.Clinical screening - A detailed case history proforma was specially prepared for this purpose. All the mentioned points were recorded in this proforma before initiating the trial.

A. Pre Trial Screening :- This was done before the administration of trial drug Complete medical history, Routine haematological tests, Some of the biochemical tests, Ashtavidha and Dashavidha pariksha  was also done .

B.  Follow up Screening :-  OPD patients were called for follow up on every 15th day to evaluate and to observe the effects or adverse effects of treatment on their clinical status. The routine gradation of sign and symptoms were recorded fortnightly.

 

Duration of clinical trial: 60 days

 

Criteria for Assessment: All the patients were assessed for relief in signs and symptoms and objective parameters after the completion of trial. To give objectivity to subjective symptoms grading/scoring system was adopted which is as follows:

 

SandhiShula (pain) Score

•          No pain - 0

•          Mild pain - 1

•          Moderate pain but no difficulty in walking - 2

•          Slight difficulty in walking due to pain - 3

•          Severe difficulty in walking – 4

 

Sandhishotha score:

•          No swelling - 0

•          Slight swelling - 1

•          Moderate swelling - 2

•          Severe Swelling -3

 

Akunchana Prasaranjanya Vedana (pain during flexion & extension) score:

•          No pain - 0

•          Pain without winching of face - 1

•          Pain with winching of face - 2

•          Prevent complete flexion - 3

•          Does not allow passive movement – 4

 

Sandhigraha (Stiffness) score:

•          No Stiffness - 0

•          Mild stiffness - 1

•          Moderate stiffness - 2

•          Severe difficulty due to stiffness - 3

•          Severe stiffness more than 15 minutes and less than 45 minute. – 4.

Sandhisphutan (Crepitus) score:

•          No crepitus - 0

•          Palpable crepitus - 1

•          Audible crepitus – 2

•          Crepitus on walking. -3

Sparshashayata (Score):

•          No tenderness - 0

•          Patient says tenderness - 1

•          Winching of face on touch - 2

•          Does not allow to touch the joint – 3

 

LABORATORY INVESTIGATION

•          No laboratory studies are diagnostic for O.A. Laboratory tests help in differential differentiation diagnosis of OA with Rhumatic Arthritis, Gout, Aamvata and Koshtrukashirsa .

•          The haematological tests like Haemoglobin, total count of WBC, ESR, RBS, S. urea, S. Creatinine, S. calcium, S. uric acid, RA factor, and CRP test are done for routine examination and rule out any differential diagnosis.

•          Radiological examination: - In the present study, Radiological examination was done before start the clinical trial for diagnostic purpose, stage of diseases and deformities.

 

Statistical analysis:

The information gathered regarding demographic data is given in percentage. The scoring of criteria's assessment was analyzed statistically in terms of B.T. (Before treatment), A.T. (After treatment), S.D. (Standard Deviation) and S.E. (Standard Error). Paired "t" test was carried out.

The obtained results were interpreted as:

•          Insignificant P>0.05

•          Significant P<0.01, P<0.05

•          Highly significant P<0.001.

 

                Result: Clinical Improvement

 EFFECT OF THERAPY

Group – A

TABLE- 1: The pattern of clinical recovery in various subjective parameter of Sandhivaat (osteoarthritis).

Symptom	Mean Score		%  Relief	S.D	S.E	‘t’ Value	‘p’ Value
	B.T	A.T
Sandhishula	2.705	2.23	17.39	0.514	0.12	3.77	< .05
Sandhishotha	1.352	0.882	34.72	0.514	0.12	3.77	< .05
Akunchan Prasarana vedana	1.176	0.823	25	0.469	0.11	2.58	< .05
Sandhigraha	1.235	0.529	38.09	0.51	0.12	3.77	< .05
Sandhisphutana	1.152	1.41	7.69	0.332	0.08	1.46	>.05
Sparsha Asahyata	0.352	0.176	50	0.39	0.09	1.85	>.05

 

EFFECT OF THERAPY

Group – B

 TABLE- 2: The pattern of clinical recovery in various subjective parameter of sandhivaat (osteoarthritis).

 

Symptom	Mean Score		%  Relief	S.D	S.E	‘t’ Value	‘p’ Value
	B.T	A.T
SandhiShula	2.66	2.22	14.58	0.501	0.11	3.28	<0.05
Sandhishotha	1.05	0.944	15.78	0.38	0.09	1.84	>0.05
Akunchan Prasarana vedana	1.33	0.83	33.33	0.51	0.12	3.68	<0.05
Sandhigraha	1.55	1.16	21.42	0.48	0.11	2.91	<0.05
Sandhisphutana	1.61	1.44	10.34	0.38	0.09	1.84	>0.05
Sparsha Asahyata	0.27	0.16	40	0.32	0.76	1.45	>0.05

EFFECT OF THERAPY

Group – C

TABLE- 3: The pattern of clinical recovery in various subjective parameter of sandhivaat (osteoarthritis).

Symptom	Mean Score		%  Relief	S.D	S.E	‘t’ Value	‘p’ Value
	B.T	A.T
Sandhishula	3.272	2.16	32.75	0.89	0.21	5.0	< .001
Sandhishotha	1.61	0.61	58.62	0.70	0.16	5.66	< .001
Akunchan Prasarana vedana	1.5	0.83	48.14	0.54	0.12	5.59	< .001
Sandhigraha	1.22	0.61	36.36	0.54	0.12	3.44	< .05
Sandhisphutana	2.05	1.88	10.81	0.44	0.10	2.10	> .05
Sparsha Asahyata	0.55	0.27	72.00	0.54	0.12	3.09	< .05

 

Table-4 : Inter group Comparision in subjective parameter of

                        sandhivaat (osteoarthritis).

Cardinal Symptoms	PERCENTAGE RELIEF
	Group-A		Group-B		Group-C
	% Relief	“P” Value	% Relief	“P” Value	% Relief	“P” Value
Sandhishula	17.39 %	< .05	14.58 %	<0.05	32.75%	< .001
Sandhishotha	34.72 %	< .05	15.78%	>0.05	58.62 %	< .001
Akunchana Prasarana vedana	25 %	< .05	33.33%	<0.05	48.14 %	< .001
Sandhigraha	38.09 %	< .05	21.42 %	<0.05	36.36 %	< .05
Sandhisphutana	7.69 %	>.05	10.34 %	>0.05	10.81 %	> .05
Sparshasahyata	50 %	>.05	40 %	>0.05	72 %	< .05

 

 

Discussion:  Sandhivata is a dhatu kshyajanya vata vyadhi. It is an age-related disorder. Based on symptoms, it can be correlated with osteoarthritis. It is a multifactorial, non-inflammatory degenerative disorder. The Pathological changes in major synovial joints are gradual thinning of cartilage and osteophyte formation with irreversible degenerative changes. According to the literary profile, Sandhivata is asadhya, or incurable in nature. The medication can give only symptomatic relief.

Ashwagandha and Amrita are Tikta Dravya having vatahar, aganidipaniya, and Rasayana properties that redeem the vitalized vata and degenerative changes in Sandhivata.

Samprapti Ghataka :

Sandhivaat is basically a dhatu kshayajanya (degenerative) vata dominant disorder in the old age group. To counter balance the basic pathology of the disorder, i.e., the degenerative process, drugs which have Dipaniya, Rasayan, Brimhana, and Vatahar property are preferred for treating Sandhivata.

•          The drugs Ashwagandha and Amrita, having a unique combination of Ushna virya, Madhur vipaka, and the above-mentioned properties, will definitely serve the purpose.

•          Ashwagandha have Tikta rasa with Balya karma, which differenciate it with other drug. Tikta rasa has agnidipan and pachan property.

•          Amrita have also Tikta rasa and agni dipaniya property due to Vayu and Aakash mahabhut. Tikta Rasa has Vayu and Akasha Mahabhuta in dominance. Hence, it has affinity towards the body elements like Asthi, having Vayu and Akasha Mahabhuta in dominance, and also destroys khavagunaya of Sandhi due to its akasha mahabhut, which is ashraya of vitalized vata.

•          Ashwagandha and Amrita are Ushna, and tikta, laghu rasayan dravya, which clean closed channels to provide nutrition to every cell of the body and improve digestion (Dhatvagni) and metabolism, which improve the structural and functional pattern of dhatu. As a result, Asthi dhatu and Majja dhatu get stable and get kshaya of their respective dhatus, which will be decreased. It can be said that it slows down the degenerative process. Ashwagandha and Amrita have vatashamak property due to ushna virya. So it reduces the cardinal symptom of Sandhivata. 

•          Ashwagandha and Amrita are both drugs that have madhur vipaka. In Sutraasthan, Acharya Vaghbhat states , Rasa and vipaka have the same therupetic action, so both have excellent efficacy and Vatshamak property due to Madhur vipaka.

•          Ashwagandha has Guna Snigdh , Virya ushna and Vipaka Madhur, which help in pacifying aggrevated vata and Amrita has also virya ushna and vipaka madhur, which help in control elevated vata dosha.

Conclusion: Comparing the symptomatic improvement in all group ,a statistically significant difference was found in all three groups on compiling the effect of therapy. It may be said that the Ashwagandha of Group-A is more efficient than that of Group-B. (Amrita). However, Group-C (Ashwagandha + Amrita) was shown to be more effective in treating the patients than either Group-A or Group-B. The trial drug has given promising results by showing improvement in the signs and symptoms of Sandhivata. This study overall conclude that both drug are Ashwagandha and Amrita are effective in sandhivaat. These drugs have zero side effects when used in a therapeutic setting. The therapeutic results obtained in the current study are satisfactory. Their production costs are low, making them affordable to any social group. There for Ashwagandha and Amrita are used as a preventative and therapeutic treatment of Sandhivata.

 

References

1.          The charaka samhita of Agnivesh, vidyoti hindi commentary by Pt. Kashi Nath Shastri and Dr. Gorakh Nath sastri,13th edition,1986, chaukhamba bharti academy. varanasi, sutraasthan 9/7

2.         Encyclopaedia of Economic Botany, vikash kumarsharma, sunil kr sehanai, volume-4, first edition-2012, Published by-campus book international, 4831/24.prahlad street, ansari road, New –Delhi 110002

3.         Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): a review. Altern Med Rev. 2000 Aug:5(4):334-46. PMID: 10956379.

4.         Iuvone T, Esposito G, Capasso F, Izzo A. Induction of nitric oxide synthase expression by Withania somnifera in macrophages. Life Sci 2003:72:1617- 1625.

5.         A. Kumar, S.K. Kulkarni. Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice. Indian J. Exp. Biol. 44(1): 45-48 (2006).Prakash J, Gupta SK, Dinda AK. Withania somnifera root extract prevents DMBA-induced squamous cell carcinoma of skin in Swiss albino mice. Nutr Cancer 2002:42:91-97.

6.         12 Jayaprakasam B, Zhang Y, Seeram N, Nair M. Growth inhibition of tumor cell lines by withanolides from Withania somnifera leaves. Life Sci 2003:74:125-132.

7.         N.P. Visavadiya, A.V. Narasimhacharya. Hypocholesteremic and antioxidant effects of Withania somnifera (Dunal) in hypercholesteremic rats. Phytomedicine.

8.         Bhaw prakash nighantu3/1-5

9.         Kaushik sutra 22-1-50

10.       GuduchiswasotiktAkashayoshna ……..kanduvisharpnaashini. dhan.ni. guduchyadi

varga.1/5-7

11.        M.p nighantu. abhyadi varga.

12.       Chhinnayah swarasam vapi………..divyarupobhawennarah.

13.       Guduchiswarasa…………. payayattadhalimake.sodhal Ni Hallimak

14.       Vasak ewaraasam  vaapi Gudhuchya Rasamev cha. Sodhal Ni. Vatajanya Raktapradar.

15.       Guduchi madhura pake ……….kasan rasayani. Kaidev Ni Aushadhi .varga1/9-10

16.       Sangrahini kashayoshana …………Hridrogavatanut.

17.        BhavaprAkashnighu. Guduchayadi varga

18.       Gudhuchigurashnavirya…………bharmaharini      Rajnighantu guduchayadivarga

19.       Kwatho jirnaJwaramHanti Guduchya Pippaliyutam.   Shar Samh.M.K 2/44

20.      Amritairandvasanam..............Vataraktami jayetdhruwam.Shar.Sam.M.K.2/133

21.       Amritaya rasah kshoudrayuktah Sarwapramchjit Shar Sam.M.K.1/7

22.       Kamlayam...... Rasoathwa jayatikamlam.Shar.Sam. M.K.1/9 21. Bhav Prakashni.

Guduchyadi Varga.

23.       Madhuk Madhuparni Prishniparni Ambasthaki Samanga............... Sandhaniyani

 bhawanti.

24.       R. Mehra, T. Naved, M. Arora, S. Madan, Standardization and evaluation of

formulation parameters of Tinospora cordifolia tablet, J. Adv. Pharm. Educ. Res. 3 (2013) 440–449.

25.         G. Abiramasundari, K.R. Sumalatha, M. Sreepriya, Effects of Tinospora cordifolia (Menispermaceae) on the proliferation, osteogenic differentiation and mineralization of osteoblast model systems in-vitro, J. Ethnopharmacol. 141 (2012) 474–480.

26.         Chemistry and pharmacology of ayurvedic medicinal plants by VD MUKUND SABNIS, B.A.M.S,MD CHAUKHAMBA AMARABHARTI PRAKASHAN. POST  BOX NO-1138,VARANASI.

27.       Anonymous, the Ayurvedic Pharmacopoeia of India. Part I. first ed.. Vol. 1, Department of AYUSH, Ministry of Health and FW, New Delhi (2001) 53-55.

28.       A.D. Chougale, V.A. Ghadyale, S.N. Panaskar, A.U. Arvindekar, Alpha-glucosidase inhibition by stem extract of Tinospora cordifolia, J. Enzym. Inhib. Med. Chem. 24 (2009) 998–1001.

29.       M.B. Patel, S.M. Mishra, Magnoflorine from Tinospora cordifolia stem inhibits α-glucosidase   and its antiglycemic in rats, J. Funct. Foods 4 (2012) 79–86.

30.      D. Singh, P.K. Chaudhuri, Chemistry and pharmacology of Tinospora cordifolia, Nat.  Prod. Commun. 12 (2017) 299–308.

31.       P.P.M. Stanely, V.P. Menon, G. GunaseKharam, Hypolipidaemic action of Tinospora cordifolia roots in alloxan-induced diabetic rats, J. Ethnopharmacol. 64 (1999) 53–57.

32.       D.N.K. Sarma, R.L. Khosa, J.P.N. Chaurasia, M. Sahai, Antistress activity of Tinospora cordifolia and Centella asiatica extracts, Phytother Res. 10 (1996).

33.       P. Baghel, Plant of versatile vroperties of Tinospora cordifolia (Guduchi), IJAIR 5 (2017) 751–753.

34.       B. Sharma, R. Dabur, Protective effects of Tinospora cordifolia on hepatic and gastrointestinal toxicity induced by chronic and moderate alcoholism, Alcohol 51 (2016) 1–10.

35.       R. Jeyachandran, T.F. Xavier, S.P. Anand, Antibacterial activity of stem extracts of Tinospora cordifolia (willd) hook, Anc. Sci. Life. Res. 25 (2003) 40–43.

36.       A.S. Narayanan, S.S. Raja, K. Ponmurugan, S.C. Kandekar, K. Natarajaseenivasan,  Maripandi, Q.A. Mandeel, Antibacterial activity of selected medicinal plants against multiple antibiotic resistant uropathogens, Benef. Microbes 2 (2011) 235–243

37.       T. Shanbhag, S. Shenoy, M.C. Rao, Wound healing profile of Tinospora cordifolia, Indian Drugs 42 (2005) 217–221.

38.       H. Ali, S. Dixit, Extraction optimization of Tinospora cordifolia and assessment of the anticancer activity of its alkaloid palmatine, Sci. World J 28 (2013) 1–10.

39.       R. Verma, H.S. Chaudhary, R.C. Agrawal, Evaluation of antcarcinogenic and antmutagenic effect of Tinospora cordifolia in experimental animals, J. Chem.Pharm. Res. 3 (2011) 877–881.

40.      The Ayurvedic Formulary of India. Part‑1. 2nd ed. New Delhi: Controller of Publications, Ministry of Health and Family Welfare, Govt. of India: 2003. p. 560.

41.       Nagarjuna. In: Sharma HS, editor. Rasendra Mangalam of Nagarjuna. 3\112. Varanasi: Choukhamba Orientalia: 2008. p. 84.

42.       Shastri B, editor. Commentary Vidhyotani of Shastri Laxmipati sastri  on  Yogaratnakara . reprint-2021,: Choukhamba prakashan,:Varanasi 2021 p. 383

43.       Sharma H. Rasa Yoga Sagara. Reprint ed. Varanasi: Chaukhamba Krishnadas Academy: 2004. p. 378.

44.       Acharya YT. Siddha Yoga Sangraha. Rajyakshma Urahkshatadhikar. 13th ed., Ch. 14. Nagpur: Shri Baidhnath Ayurved Bhavan Ltd.: 2008. p. 83‑4.

45.       Seasonal variations in physicochemical profiles of Guduchi Satva (starchy substance from Tinospora cordifolia [Willd.] Miers),Rohit Sharma, Hetal Amin1, Galib R, P. K. PrajapatiDepartments of Rasashastra and Bhaishajya Kalpana, and 1Basic Principles, I.P.G.T. and R.A., Gujarat Ayurved University, Jamnagar, Gujarat, India.

46.       Sharma R, Harisha CR, Galib R, Patgiri BJ, Prajapati PK.Quantitative estimation of Satva extracted from different stem sizes of Guduchi (Tinospora cordifolia (Willd.) Miers. J Pharm Sci Innov 2012:1:38‑40.

47.       Charaka Samhita of Agnivesha, Ambika Data Sartri: Kalpasthana: Madanakalpa. Reprint ed. ch. 1. Ver.10. Varanasi: Chaukhamba Orientalia: 2011.

48.       Acharya YT. Sushruta Samhita of Sushruta: Sutrasthana: Bhumipravibhagiya. Reprint ed. ch. 37. Ver. 5. Varanasi: Chaukhamba Sanskrita Sansthana: 2010. .

49.       Sharma P.V, Drvyaguna Vijñana, Vol - I, Chaukhamba Bharati Academy, Varanasi, 1994: 48.

50.      Bhava Mishra, Bhavaprakasa, Edt. Mishra Pt.Brahma Shankar, Part-1, Guduchyadi Varga, Chaukhamba publication, Varanasi, 1988: 270.

51.       Ayurvedic Formulary of India, Part – I, ISMH, G.O.I, 2003,14:1: 163.

52.       Sharma H. Rasa Yoga Sagara. Reprint ed. Varanasi: Chaukhamba Krishnadas Academy: 2004. p. 378.

53.       Shastri B, editor. Commentary Vidhyotani of Shastri Laxmipati sastri  on Yogaratnakara  reprint-2021 ,: Choukhamba prAkashan,:Varanasi 2021 p. 383

54.       Reddy KR. Ausadha Kalpana. Bhaishajya Kalpana Vijnanam. 2nd ed. Ch. 4.

Varanasi:  Chaukhamba Samskrita Bhawan: 2005. p. 234.

55.       Hiremath SG. Satva Kalpana. A Text Book Bhaishajya Kalpana. 2nd revised ed. Part Ch. 19. Varanasi: Chaukhamba Orientalia: 2005. p. 220.

56.       Ayurvedic pharmacopoeia of India, part-1, volume-VI, appendix 2.4.1, pg no 275. 

57.       Laboratory Guide for the Analysis of Ayurveda and Siddha Formulations, CCRAS,

2010.

58.       BHĀVAPRAKĀSA  OF ŚRĪ BHĀVAMISRA By  Bhisagratna  Pandit  Śrī Brahma Sankara Miśra,  

Publishers: Chaukhambha  Sanskrit  Sansthan, Post Box. No. 1139 Varanasi-221001 (India), ninth

edition, page no-265.

59.       Ashtanga Hridaya composed by Vagbhata with the commentaries Sarvanga sundari  of Arunadatta and Ayurveda Rasayana of Hemadri, Chaukhambha Orientalia,   Varanasi. Sutraasthan 19/8-14.

60.      Ashtanga Hridaya composed by Vagbhata with the commentaries Sarvanga sundari of Arunadatta and Ayurveda Rasayana of Hemadri, Chaukhambha Orientalia, Varanasi. Sutraasthan 20/36-41 .

61.       The charaka samhita of Agnivesh,vidyoti hindi commentary by Pt. Kashi Nath Shastri and Dr. Gorakh Nath sastri,13th edition,1986, chaukhamba bharti academy.varanasi, Sutraasthan 11/48.

62.       Sushruta Samhita of maharshi Sushruta:by Kviraj Ambikadutta Sastri : Reprint ed 2018. Varanasi: Chaukhamba Sanskrita Sansthana: sharirasthan 6/3.

63.       Sushruta Samhita of maharshi Sushruta:by Kviraj Ambikadutta Sastri : Reprint ed 2018. Varanasi: Chaukhamba Sanskrita Sansthana: Nidhanasthan 1/17-18.

64.       Sushruta Samhita of maharshi Sushruta:by Kviraj Ambikadutta Sastri : Reprint ed 2018. Varanasi: Chaukhamba Sanskrita Sansthana: Sutraasthan  21/5.

65.       The charaka samhita of Agnivesh,vidyoti hindi commentary by Pt. Kashi Nath Shastri and Dr. Gorakh Nath sastri,13th edition,1986, chaukhamba bharti academy.varanasi, sutraasthan.

66.      The charaka samhita of Agnivesh,vidyoti hindi commentary by Pt. Kashi Nath Shastri and Dr. Gorakh Nath sastri,13th edition,1986, chaukhamba bharti academy.varanasi, sutraasthan 1/59,and  12/4.

67.       Robbins and Cotran Pathologic Basis of Disease Eighth Edition. page no-1236

68.      Harrison's, Principles of Internal Medicine, 18th edition, Volume 2nd McGraw-   Hill, Medical Publishing Division, New York. page no- 2828,2829.

69.      Harrison's, Principles of Internal Medicine, 18th edition, Volume 2nd McGraw- Hill, Medical Publishing Division, New York. page no- 2830 .

70.       Harrison's, Principles of Internal Medicine, 18th edition, Volume 2nd McGraw-    Hill, Medical Publishing Division, New York. page no- 2832.

71.        Harrison's, Principles of Internal Medicine, 18th edition, Volume 2nd McGraw-        Hill,Medical Publishing Division, New York. page no- 2831.

72.       Robbins and Cotran Pathologic Basis of Disease Eighth Edition. page no-1236

73.       Osteoarthritis and the metabolic syndrome: more evidence that the etiology of OA is       different in men and   women by K.M. Huffman and W.E. Kraus PMC 2013 APR         30, PMCID: PMC3639485

74.       Davidson's Principles and Practice of Medicine 21st Edition, musculoskeletal diseases. Page no-1085

75.       Current Medical Diagnosis & Treatment 2021 Special India Edition Maxine A.   Papadakis Stephen J. Mcphee Associate Editor Michael W. Rabow Mc Graw Hill Lange, Page No-852, Chap-20.